Although the activity of the mTOR inhibitor everolimus has been reported in patients with luminal and HER2+ breast cancers [7, 8], results of clinical trials with mTOR-specific inhibitors in TNBC have not been published yet. This evidence concerns the gene MTOR and breast carcinoma.